Tag: Therapeutics

Plasma Fractionation Market to Exhibit 6.2% CAGR, Development of Various Therapeutics to Boost Industry | Fortune Business Insights

The “plasma fractionation market size” is anticipated to reach USD 38.65 Billion by 2026. Increasing number of patients with congenital disorders, along with rising research and development (R&D) activities, will drive the market. Fortune Business Insights has published a report, titled “Plasma Fractionation Market Size, Share & Industry Analysis, By Product Type (Albumin, Immunoglobulin (Intravenous Immunoglobulin and Subcutaneous Immunoglobulin), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen concentrates and Others), Protease Inhibitors and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology and Others), By End User (Hospitals & Clinics, Clinical Research Laboratories and Others (Academic Institutes, etc.)) and Geography Forecast, 2019-2026.” As per the report, the market was worth USD 24.07 Billion in 2018. Furthermore, it is likely to exhibit a CAGR of 6.2% during the projected horizon, 2019-2016.

Key Players Operating in The Plasma Fractionation Market Include:

Key players are involved in mergers and acquisition

Read More

Xerostomia Therapeutics Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Apotex Inc. and Church & Dwight Co. Inc. | Technavio

LONDON–(BUSINESS WIRE)–The global xerostomia therapeutics market size is expected to grow by USD 133.27 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of 4%.

For the Right Perspective & Competitive Insights- Request Free Sample Report on Pandemic Recovery Analysis

Read the 120-page report with TOC on “Xerostomia Therapeutics Market Analysis Report by Product (OTC and Prescription) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024”. Gain competitive intelligence about market leaders. Track key industry opportunities, trends and threats. Information on marketing, brand, strategy and market development, sales and supply functions. https://www.technavio.com/report/xerostomia-therapeutics-market-industry-analysis

Xerostomia therapeutics market is driven by the increasing awareness of

Read More

Xerostomia Therapeutics Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Apotex Inc. and Church & Dwight Co. Inc.

The global xerostomia therapeutics market size is expected to grow by USD 133.27 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of 4%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005704/en/

Technavio has announced its latest market research report titled Global Xerostomia Therapeutics Market 2020-2024 (Graphic: Business Wire).

For the Right Perspective & Competitive Insights- Request Free Sample Report on Pandemic Recovery Analysis

Read the 120-page report with TOC on “Xerostomia Therapeutics Market Analysis Report by Product (OTC and Prescription) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024”. Gain competitive intelligence about market leaders. Track key industry opportunities, trends

Read More

We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So, the natural question for Forma Therapeutics Holdings (NASDAQ:FMTX) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company’s annual negative free cash flow, henceforth referring to it as the ‘cash burn’. We’ll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Forma Therapeutics Holdings

When Might Forma Therapeutics Holdings Run Out Of Money?

A cash runway is defined as the length of time it would take a company

Read More

Pomerantz Law Firm Announces the Filing of a Class Action against Odonate Therapeutics, Inc. and Certain Officers – ODT

NEW YORK, Sept. 16, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Odonate Therapeutics, Inc.  (“Odonate” or the “Company”) (NASDAQ: ODT) and certain of its officers.   The class action, filed in United States District Court for the Southern District of California, and docketed under 20-cv-01828, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Odonate securities between December 7, 2017, and August 21, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Odonate securities during the class period,

Read More

CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership

SUZHOU, China, Sept. 10, 2020 /PRNewswire/ — CMAB Biopharma (Suzhou) Inc. (“CMAB”), and Laekna Therapeutics Shanghai Co., Ltd. (“Laekna Therapeutics”), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clinical trial and future commercialization.

According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005). Services to be provided by CMAB include technology transfer, process development, GMP clinical drug substance and drug product manufacturing to support IND filing in China and in the US. These services will facilitate the global development and future commercialization of LAE005.

Laekna Therapeutics is a biotechnology innovation company focusing on the research and development of new generation of small molecules for target therapy and antibodies in the field of oncology and liver diseases. In February 2020, Laekna

Read More

Renal Therapeutics Market: Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast To 2026

The MarketWatch News Department was not involved in the creation of this content.

Sep 07, 2020 (The Expresswire) —
The global renal therapeutic market is projected to gain impetus from the rising number of geriatric population across the globe. According to a report by Fortune Business Insights, titled, “Renal Therapeutics Market Size, Share and Global Trend by Application (Chronic kidney disease, Diabetes, Kidney stone disease, Kidney failure, Others), by Drug Class (Angiotensin-II receptor blockers, ACE Inhibitors, Calcium channel blockers, Beta-blockers, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026,” the global renal therapeutics market is likely to grow at a fast pace due to the increasing number of kidney diseases among the populace.

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/renal-therapeutics-market-100583

Leading Players operating in the Renal Therapeutics Market are:

Key players are involved in mergers and acquisition to strengthen their market position.

Read More